QGE031 (Ligelizumab)

ligelizumab · Novartis Pharmaceuticals

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for QGE031 (Ligelizumab), covering 2021-08-24 to 2024-10-08. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy [Phase 3]